Systematic review of dasatinib in chronic myeloid leukemia
Massimo Breccia, Adriano Salaroli, Matteo Molica, Giuliana Alimena Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy Abstract: Dasatinib is a dual tyrosine kinase inhibitor active against ABL and Src family kinases, and is approved for the treatment of chronic m...
Main Authors: | Breccia M, Salaroli A, Molica M, Alimena G |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-03-01
|
Series: | OncoTargets and Therapy |
Online Access: | http://www.dovepress.com/systematic-review-of-dasatinib-in-chronic-myeloid-leukemia-a12602 |
Similar Items
-
Dasatinib in chronic myeloid leukemia: a review
by: Dolly G Aguilera, et al.
Published: (2009-03-01) -
DASATINIB IN CHRONIC MYELOID LEUKEMIA
by: Mojca Modic
Published: (2008-04-01) -
Use of dasatinib in chronic myeloid leukemia therapy
by: O. Yu. Vinogradova, et al.
Published: (2008-12-01) -
Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
by: Radhakrishnan Ramchandren, et al.
Published: (2009-05-01) -
The role of dasatinib in the management of chronic myeloid leukemia
by: Chen R, et al.
Published: (2015-02-01)